Stockscreener 앱 받기
0.00
100.00%
-3.65
시간 외 거래:
3.66
3.66
+
Revance Therapeutics Inc 주식(RVNC)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Raises Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Investigation announced for Long-Term Investors in Revance - openPR.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
JPMorgan Chase & Co. Sells 2,335,359 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Reduces Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Wellington Management Group LLP Trims Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Norges Bank Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
KLP Kapitalforvaltning AS Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Commonwealth Equity Services LLC Cuts Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Recommendation of “Hold” from Analysts - Defense World
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - Defense World
BIOJUVE® Honoured as Best Cosmetics of the Year at AMWC 2025 in Monaco - The Malaysian Reserve
Public market insider buying at Prime Mining (PRYM) - The Globe and Mail
RVNC INVESTIGATION: Hagens Berman Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys Now, Firm Investigating Possible Securities Law Violations - ACCESS Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bay Area drug veteran heads New Zealand company's oral ketamine spinoff targeting depression - The Business Journals
Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022RVNC - ACCESS Newswire
Crown Laboratories rebrands as Revance following acquisition - MSN
Johnson City-based Crown Labs now operating as ‘Revance’ - WJHL
Crown Laboratories Now Operates Under the Name Revance - PR Newswire
Charles Schwab Investment Management Inc. Grows Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Purchased by Charles Schwab Investment Management Inc. - The AM Reporter
Revance Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire
Bank of New York Mellon Corp Sells 18,519 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important February 8 Deadline in Securities Class Action – RVNC - Business Wire
Lost Money on Revance Therapeutics, Inc. (RVNC)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm - Louisiana First News
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $8.39 Average Price Target from Brokerages - Defense World
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.com - Defense World
Major Catalyst Alert: Dermata's Phase 3 Acne Treatment Results Coming in Weeks - StockTitan
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - Defense World
Rhumbline Advisers Boosts Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
ForexTV | Small Business Resources - ForexTV.com
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC) - Stockhouse Publishing
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025RVNC - ACCESS Newswire
Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class ActionRVNC - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
RVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, - GlobeNewswire
Deadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
Revance Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
2025-03-03 | Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline | Press Release - Stockhouse Publishing
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class ActionRVNC - PR Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
2025-03-02 | Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | Press Release - Stockhouse Publishing
0.24%
36.06%
자본화:
|
볼륨(24시간):